ArticleJournal of gastroenterology2024

Development of a novel oncolytic adenovirus controlled by CDX2 promoter for esophageal adenocarcinoma therapy.

Naohiko Nakamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.